Stockscreener 앱 받기
1.78
6.02%
0.12
전일 마감가:
$1.66
열려 있는:
$1.67
하루 거래량:
35,494
Relative Volume:
0.94
시가총액:
$9.74M
수익:
-
순이익/손실:
$-14.29M
주가수익비율:
-0.4461
EPS:
-3.99
순현금흐름:
$-12.27M
1주 성능:
+3.53%
1개월 성능:
+7.65%
6개월 성능:
-56.54%
1년 성능:
-56.00%
1일 변동 폭
$1.6601
$1.80
1주일 범위
$1.62
$1.80
52주 변동 폭
$1.412
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
APRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.76 | 9.40M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.50 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.59 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.54 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
565.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.85 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-06-22 | 개시 | H.C. Wainwright | Neutral |
| 2020-04-21 | 개시 | Robert W. Baird | Outperform |
| 2019-10-28 | 개시 | JP Morgan | Neutral |
| 2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Aprea Therapeutics Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - PrintWeekIndia
What analysts say about Aprea Therapeutics Inc. stockExplosive trading opportunities - PrintWeekIndia
Is Aprea Therapeutics Inc. a good long term investmentFree Capital Efficiency Planning - Autocar Professional
What drives Aprea Therapeutics Inc. stock priceHigh-yield portfolio picks - Autocar Professional
Franklin Covey Co. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com
What analysts say about AMBO stockExplosive earning power - Jammu Links News
Why Aprea Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Courses - Newser
What makes Aprea Therapeutics Inc. stock price move sharplyFree Access to Investment Community - Newser
How Rocky Mountain Chocolate Factory Inc. stock performs during market volatilityFree Consultation - Newser
How Aprea Therapeutics Inc. stock performs during market volatilityConsistent High Return Strategy - Newser
Aprea Therapeutics Insiders Still US$86k Away From Original Investment Value - simplywall.st
Aprea Therapeutics (NASDAQ:APRE) Trading 4.4% Higher – What’s Next? - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MSN
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers - MyChesCo
Aprea Therapeutics (APRE) Reports Promising Data on APR-1051 for HPV+ Cancer | APRE Stock News - GuruFocus
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center - Morningstar
Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
CoreWeave Stock Skyrockets 137% In A Month: Hold Or Fold? - Barchart.com
Block Inc. Has Unusual Put Option ActivityShowing Bullish XYZ Investors - Barchart.com
Ostara Inc. Launches CG P2X In Western Canada: Phosphorus, Perfected - Barchart.com
Stocks In Play: WSP Global Inc. - Barchart.com
Alzheimer’s Disease Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Dry Eye Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - Barchart.com
Supporting 2SLGBTQI+ Communities For A Safer, More Equitable And Inclusive Canada - Barchart.com
Artios' AACR Data Success: What It Means For Aprea Therapeutics' ATRN-119 Program - Barchart.com
REKO INTERNATIONAL GROUP INC. TO BUY BACK UP TO 276,066 OF ITS COMMON SHARES - Barchart.com
Aprea Therapeutics Confirms Directors and Accounting Firm - TipRanks
Stocks Finish Sharply Higher On A Resilient US Labor Market - Barchart.com
Compass Refresh, Inc. Launches New Headquarters in Sulphur Springs, TX – Bringing High-Quality Exterior Maintenance Across the Southern Region - Barchart.com
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Stocks In Play: Aimia Inc. - Barchart.com
ADF GROUP INC. Q1-2026 CONFERENCE CALL INVITATION - Barchart.com
BNP Paribas Financial Markets Takes $43,000 Position in Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
Galaxy Digital Inc. Announces Public Offering Of Common Stock - Barchart.com
Vermilion Energy Inc. Advances Strategic Portfolio Repositioning with Agreement to Sell its Saskatchewan Assets and Accelerate Debt Repayment - Barchart.com
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Ovarian Cancer Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Q2 Earnings Estimate for APRE Issued By Wedbush - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Earns “Buy” Rating from B. Riley - Defense World
The Manufacturers Life Insurance Company Sells 752 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) - Defense World
The Manufacturers Life Insurance Company Purchases 993 Shares of CTO Realty Growth, Inc. (NYSE:CTO) - Defense World
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.17%
자본화:
|
볼륨(24시간):